 For myositis: in case of management with rituximab, treatment should be discontinued. For Grade 3 or 4 endocrinopathies: withhold until clinically stable or permanently discontinue depending on severity. For hepatitis with no tumor involvement of the liver: withhold if total bilirubin increases to more than 1.5 and up to 3 times ULN, permanently discontinue if more than 3 times ULN 3.3.3 Discontinuation Treatment will be discontinued in case of following events if occur within the DLT evaluation period: Any Grade 4 adverse drug reactions (ADRs), as defined by CTCAE v5 and assessed as related to any study agent by the Investigator, except for laboratory values that are determined to not be clinically significant or single laboratory valued that resolve to Grade ≤ 1 or baseline grade within 7 days with adequate medical management. Any Grade 3 ADRs except for any of the following: oTransient flu-like symptoms or fever, which is controlled with medical management.